(Q54392042)

29 May 2018

title

TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity. (English)

1 reference

29 May 2018

author name string

E A Grimm

1

1 reference

29 May 2018

W L Crump

2

1 reference

29 May 2018

A Durett

3

1 reference

29 May 2018

J P Hester

4

1 reference

29 May 2018

S Lagoo-Deenadalayan

5

1 reference

29 May 2018

L B Owen-Schaub

6

1 reference

29 May 2018

publication date

1 January 1988

1 reference

29 May 2018

Cancer Immunology, Immunotherapy

published in

1 reference

29 May 2018

volume

27

1 reference

29 May 2018

page(s)

53-58

1 reference

29 May 2018

issue

1

1 reference

29 May 2018

https://scigraph.springernature.com/pub.10.1007/bf00205758

exact match

0 references

cites work

Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality

1 reference

12 December 2020

Lymphokine-activated killer cells. Analysis of progenitors and effectors

1 reference

12 December 2020

Increased secretion of type beta transforming growth factor accompanies viral transformation of cells

1 reference

12 December 2020

Enhancement of tumor outgrowth by tumor-associated blocking factors

1 reference

12 December 2020

Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli

1 reference

12 December 2020

Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes

1 reference

12 December 2020

Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor

1 reference

12 December 2020

Serum contains a platelet-derived transforming growth factor

1 reference

12 December 2020

Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

1 reference

12 December 2020

Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization

1 reference

12 December 2020

New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues

1 reference

12 December 2020

Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells

1 reference

12 December 2020

Transforming growth factor-beta: biological function and chemical structure

1 reference

12 December 2020

Functional differentiation of human lymphokine-activated killing (LAK) is distinct from expansion and involves dissimilar interleukin 2 receptors

1 reference

12 December 2020

The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells

1 reference

12 December 2020

The differential inhibitory effects exerted by cyclosporine and hydrocortisone on the activation of human cytotoxic lymphocytes by recombinant interleukin-2 versus allospecific CTL

1 reference

12 December 2020

Sarcoma growth factor from conditioned medium of virally transformed cells is composed of both type alpha and type beta transforming growth factors

1 reference

12 December 2020

Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes

1 reference

12 December 2020

Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis

1 reference

12 December 2020

Role of interleukin 2 and a serum suppressive factor on the induction of activated killer cells cytotoxic for autologous human melanoma cells

1 reference

12 December 2020

Immunoregulatory factors derived from human tumors. I. Immunologic and biochemical characterization of factors that suppress lymphocyte proliferative and cytotoxic responses in vitro

1 reference

12 December 2020

Presence of immunosuppressive factors in brain-tumor cyst fluid.

1 reference

12 December 2020

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

12 December 2020

T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta

1 reference

12 December 2020

In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes

1 reference

12 December 2020

Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors.

1 reference

12 December 2020

Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells

1 reference

12 December 2020

High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings

1 reference

12 December 2020

Characterization of an immunosuppressive factor derived from colon cancer cells

1 reference

12 December 2020

Inhibition of cytokine production by cyclosporin A and transforming growth factor beta

1 reference

12 December 2020

Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00205758

1 reference

29 May 2018

PubMed ID

3260821

1 reference

29 May 2018